LEE MH Reply: Oversights in Stratification and Viral Screening- A Critical Appraisal of
a MetS-Cholangiocarcinoma Cohort.
Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001370. PubMed
HUANG J Letter to the editor: Oversights in stratification and viral screening- A
critical appraisal of a MetS-cholangiocarcinoma cohort.
Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001369. PubMed
HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al Cirrhosis and age are key determinants of HCC risk in individuals with primary
sclerosing cholangitis: A multicenter longitudinal cohort study.
Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351. PubMedAbstract available
YU Y, You Y, Duan Y, Kang M, et al Multiomics approaches for identifying the PANoptosis signature and prognostic
model via a multimachine-learning computational framework for intrahepatic
cholangiocarcinoma.
Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352. PubMedAbstract available
LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or
common autoimmune penetrance?
Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326. PubMed
YANG LX, Gao Q, Shi JY, Wang ZC, et al Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in
intrahepatic cholangiocarcinoma leads to invasive growth and
epithelial-mesenchymal transition.
Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274. PubMed
SAMPLE JW A Niche Discovery: Spatial Mapping of Therapeutic Targets in Biliary Atresia.
Hepatology. 2025;81:1109-1110. PubMed
MOL B, Werner E, Culver EL, van der Meer AJ, et al Epidemiological and economical burden of cholestatic liver disease.
Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341. PubMedAbstract available
March 2025
GRONBAEK L, Vilstrup H, Jepsen P Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis -
distinct or common autoimmune penetrance?
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325. PubMed
LEVY C, Bowlus CL Erratum: Primary biliary cholangitis: Personalizing second-line therapies.
Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001275. PubMed
MACIAS RIR, Roessler S, Verstegen MMA Deciphering the spatial tumor microenvironment in intrahepatic
cholangiocarcinoma.
Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322. PubMed
CHEN TI, Chen MH, Yin SC, Lin CJ, et al Associations between metabolic syndrome and cholangiocarcinoma risk: A
large-scale population-based cohort study.
Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001312. PubMedAbstract available
SINGH Y, Eaton JE, Venkatesh SK, Welle CL, et al Deep learning analysis of magnetic resonance imaging accurately detects
early-stage perihilar cholangiocarcinoma in patients with primary sclerosing
cholangitis.
Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001314. PubMedAbstract available
GORES GJ, Malhi H The dynamic landscape of cholestatic liver disease.
Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001298. PubMed
February 2025
HONG L, Mei J, Sun X, Wu Y, et al Spatial single-cell proteomics landscape decodes the tumor microenvironmental
ecosystem of intrahepatic cholangiocarcinoma.
Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283. PubMedAbstract available
CANCADO GGL, Deeb M, Gulamhusein AF Liver transplantation for cholestatic liver diseases: Timing & disease
recurrence.
Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268. PubMedAbstract available
OLAIZOLA P, Olaizola I, Fernandez de Ara M, Lapitz A, et al Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by
impairing cancer cell viability and tumor-stroma crosstalk.
Hepatology. 2025 Feb 11. doi: 10.1097/HEP.0000000000001259. PubMedAbstract available
YU M, Sample JW, Yan IK, Takaichi S, et al Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in
preclinical cholangiocarcinoma models.
Hepatology. 2025 Feb 10. doi: 10.1097/HEP.0000000000001256. PubMedAbstract available
LI B BileMet: A new frontier in distinguishing malignant from benign biliary
conditions.
Hepatology. 2025;81:383-384. PubMed
January 2025
LI B, Ilyas SI Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new
therapies.
Hepatology. 2025 Jan 21. doi: 10.1097/HEP.0000000000001241. PubMed
RONCA V, Davies SP, Oo YH, Lleo A, et al The immunological landscape of primary biliary cholangitis: Mechanisms and
therapeutic prospects.
Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225. PubMedAbstract available
IDALSOAGA F, Arab JP Unraveling bile acid dynamics in severe obesity.
Hepatology. 2025;81:1-2. PubMed
December 2024
BITTERMANN T, Schaubel DE Obeticholic acid as second-line therapy for primary biliary cholangitis: Does
target trial emulation solve the issue?
Hepatology. 2024 Dec 20. doi: 10.1097/HEP.0000000000001198. PubMed
THI VU Q, Nishimura Y, Harada K, Ito H, et al International trends in biliary tract cancer-related mortality, 2000-2022: An
observational study of the World Health Organization mortality database.
Hepatology. 2024 Dec 19. doi: 10.1097/HEP.0000000000001200. PubMedAbstract available
LUO Y, Fraser L, Jezykowski J, Gupta NA, et al Interleukin 8-CXCR2 mediated neutrophil extracellular trap (NET) formation in
biliary atresia associated with NET-Induced stellate cell activation.
Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001195. PubMedAbstract available
CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al Stard1 promotes cholestatic liver injury and disease progression by sensitizing
to bile acid hepatotoxicity.
Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184. PubMedAbstract available
ZABRANSKY DJ, Kartalia E, Lee JW, Leatherman JM, et al Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant
cholangiocarcinoma.
Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185. PubMedAbstract available
BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis
(HEROES): A trial emulation study design.
Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174. PubMedAbstract available
November 2024
KARLSEN TH, Kaasen Jorgensen K, Bergquist A Medical treatment of primary sclerosing cholangitis: What have we learned and
where are we going?
Hepatology. 2024 Nov 22. doi: 10.1097/HEP.0000000000001172. PubMedAbstract available
LEVY C, Bowlus CL Primary Biliary Cholangitis: personalizing second-line therapies.
Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166. PubMedAbstract available
October 2024
FAN G, Tao C, Li L, Xie T, et al The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells
determined the poor prognosis in intrahepatic cholangiocarcinoma.
Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138. PubMedAbstract available
SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al Role of microbiome in autoimmune liver diseases.
Hepatology. 2024;80:965-987. PubMedAbstract available
September 2024
JALAN-SAKRIKAR N, Guicciardi ME, O'Hara SP, Azad A, et al Central role for cholangiocyte pathobiology in cholestatic liver diseases.
Hepatology. 2024 Sep 9. doi: 10.1097/HEP.0000000000001093. PubMedAbstract available
CORNILLET M, Geanon D, Bergquist A, Bjorkstrom NK, et al Immunobiology of primary sclerosing cholangitis.
Hepatology. 2024 Sep 2. doi: 10.1097/HEP.0000000000001080. PubMedAbstract available
August 2024
PANT K, Richard S, Peixoto E, Baral S, et al Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor
signaling.
Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001055. PubMedAbstract available
XIAO MH, Ma D, Wu S, Huang Z, et al Integrative single-cell and spatial transcriptomic analyses identify a pathogenic
cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.
Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001064. PubMedAbstract available
BJORNSSON ES, Devarbhavi HC Drug induced cholestatic liver diseases.
Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052. PubMedAbstract available
BANALES JM, Lapitz A, Fabris L Comparative performance of methylation DNA markers, brushing cytology, and FISH
in diagnosing malignant biliary strictures.
Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001050. PubMed
July 2024
ZHANG X, Liu H, Cai P, Huang Z, et al Mdka produced by the activated HSCs drives bipotential progenitor cell
redifferentiation during zebrafish biliary-mediated liver regeneration.
Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001031. PubMedAbstract available
SUTTON H, Sokol RJ, Kamath BM IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the
horizon?
Hepatology. 2024 Jul 25. doi: 10.1097/HEP.0000000000001032. PubMed
ZHUANG Y, Ortega-Ribera M, Szabo G Reply to: Exercise greater caution in bile acid research.
Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001017. PubMed
YI C, Chen L, Tao B, Wang X, et al Letter to the Editor: Exercise greater caution in bile acid research.
Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001013. PubMed
ZHANG L, Xie P, Li M, Zhang X, et al Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and
inflammation by inducing CEACAM1 N153 fucosylation.
Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003. PubMedAbstract available
June 2024
ZHU M, Qu M, Lv S, Pan F, et al Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma
research: Addressing key concerns in the PTPN9-FGFR2 interaction study.
Hepatology. 2024 Jun 24. doi: 10.1097/HEP.0000000000000932. PubMed
COOLEY MA, Schneider AR, Barr Fritcher EG, Milosevic D, et al Utility of methylated DNA markers for the diagnosis of malignant biliary
strictures.
Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000970. PubMedAbstract available
OH DY, Ikeda M, Lee CK, Rojas C, et al Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer:
A randomized phase 2/3 trial.
Hepatology. 2024 Jun 14. doi: 10.1097/HEP.0000000000000965. PubMedAbstract available
YANG S, Fu J, Qin W, Wang R, et al Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary
diseases.
Hepatology. 2024 Jun 11. doi: 10.1097/HEP.0000000000000957. PubMedAbstract available
HUANG YH, Loftfield E, Argirion I, Adami HO, et al Association of tea and coffee consumption and biliary tract cancer risk: The
Biliary Tract Cancers Pooling Project.
Hepatology. 2024;79:1324-1336. PubMedAbstract available
HANSEN BE, Vandriel SM, Vig P, Garner W, et al Event-free survival of maralixibat-treated patients with Alagille syndrome
compared to a real-world cohort from GALA.
Hepatology. 2024;79:1279-1292. PubMedAbstract available
May 2024
AYDIN O, Wahlstrom A, de Jonge PA, Meijnikman AS, et al An integrated analysis of bile acid metabolism in humans with severe obesity.
Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000938. PubMedAbstract available
KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al Identifying a therapeutic window of opportunity for people living with primary
sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease
with immune mediated liver injury.
Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926. PubMedAbstract available
April 2024
HITOMI Y, Ueno K, Aiba Y, Nishida N, et al A genome-wide association study identified PTPN2 as a population-specific
susceptibility gene locus for primary biliary cholangitis.
Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894. PubMedAbstract available
March 2024
JONES DE, Beuers U, Bonder A, Carbone M, et al Primary biliary cholangitis drug evaluation and regulatory approval: Where do we
go from here?
Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864. PubMedAbstract available
LAL BB, Alam S, Sibal A, Kumar K, et al Genotype correlates with clinical course and outcome of children with tight
junction protein 2 (TJP2) deficiency-related cholestasis.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828. PubMedAbstract available
AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al Predictive factors for decompensating events in cirrhotic patients with primary
biliary cholangitis under different lines of therapy.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826. PubMedAbstract available
PANDURANGI S, Mourya R, Nalluri S, Fei L, et al Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary
atresia in a large North American cohort.
Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827. PubMedAbstract available
ZHUANG Y, Szabo G Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic
liver and kidney injury? more need to be known.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816. PubMed
KELLERER M, Javed S, Casar C, Will N, et al Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the
immunopathogenesis of sclerosing cholangitis.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830. PubMedAbstract available
JIANG L, Yang Z Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate
cholestatic liver and kidney injury? ---more need to be known.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813. PubMed
LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al Autoimmune diseases in primary sclerosing cholangitis and their first-degree
relatives.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823. PubMedAbstract available
February 2024
ZHANG H, Zhu K, Zhang R, Guo Y, et al Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node
metastases microenvironment.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784. PubMedAbstract available
January 2024
WILBUR HC, Soares HP, Azad NS Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and
limitations.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760. PubMedAbstract available
BARGELLINI I, Rimassa L, Masi G SIRT and chemotherapy in unresectable iCCA: Ready to take off.
Hepatology. 2024;79:9-11. PubMed
CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al Adequate versus deep response to ursodeoxycholic acid in primary biliary
cholangitis: To what extent and under what conditions is normal alkaline
phosphatase level associated with complication-free survival gain?
Hepatology. 2024;79:39-48. PubMedAbstract available
December 2023
CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al Reply: Improving access to transient elastography data for Real-World Prognostic
Applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746. PubMed
WIEGAND J, Franke A, Stein K, Trautwein C, et al Letter to the Editor: Improving access to transient elastography data for
real-world prognostic applications in primary biliary cholangitis.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744. PubMed
KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary
biliary cholangitis.
Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728. PubMedAbstract available
November 2023
GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents
parenteral nutrition associated cholestasis in mice.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690. PubMedAbstract available
GEHL V, O'Rourke CJ, Andersen JB Immunogenomics of cholangiocarcinoma.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688. PubMedAbstract available
HE S, Peng Y, Wei Q Letter to the Editor: Lack of complete biochemical response in autoimmune
hepatitis leads to adverse outcome: First report of the IAIHG retrospective
registry.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685. PubMed
SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al Reply - Lack of complete biochemical response in autoimmune hepatitis leads to
adverse outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689. PubMed
LIU ZP, Sun XH, Yu C, Yin XY, et al Letter to the Editor: How to define the futile outcome in patients undergoing
surgery for perihilar cholangiocarcinoma?
Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651. PubMed
NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes
in mouse models of Alagille syndrome.
Hepatology. 2023;78:1337-1351. PubMedAbstract available
YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al Metabolic reprogramming and its clinical implication for liver cancer.
Hepatology. 2023;78:1602-1624. PubMedAbstract available
October 2023
RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al Reply: "How to define the futile outcome in patients undergoing surgery for
perihilar cholangiocarcinoma".
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659. PubMed
SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al Cystic fibrosis screening, evaluation and management of hepatobiliary disease
consensus recommendations.
Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646. PubMedAbstract available
HU YF, Ma WJ, Jin YW, Li FY, et al Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based
scheme beats out a gemcitabine-based scheme for the win.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634. PubMed
Erratum: Modulation of the tryptophan hydroxylase 1/monoamine
oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis
regulates biliary proliferation and liver fibrosis during cholestasis.
Hepatology. 2023;78:E86. PubMed
September 2023
GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al Telomere length and risk of cirrhosis, hepatocellular carcinoma, and
cholangiocarcinoma in 63,272 individuals from the general population.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608. PubMedAbstract available
ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory
responses and fibrosis in cholestasis-induced liver and kidney injury via
regulation of ZBP1.
Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611. PubMedAbstract available
SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al Lack of complete biochemical response in autoimmune hepatitis leads to adverse
outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589. PubMedAbstract available
August 2023
PEISELER M, Tacke F Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic
liver disease.
Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576. PubMed
RATTI F, Marino R, Olthof PB, Pratschke J, et al Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine
learning analytics model to optimize treatment allocation.
Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554. PubMedAbstract available
DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al Osteopontin characterizes bile duct associated macrophages and correlates with
liver fibrosis severity in primary sclerosing cholangitis.
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557. PubMedAbstract available
BOWLUS CL, Levy C Optimizing treatment of primary biliary cholangitis: Is good, good enough?
Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556. PubMed
July 2023
ZHAO L, Liu J, Li K, Zhang C, et al PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates
pemigatinib effect in cholangiocarcinoma.
Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552. PubMedAbstract available
LI Y, Li B, Xiao X, Qian Q, et al Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse
models of primary sclerosing cholangitis.
Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549. PubMedAbstract available
EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al Chemotherapy with or without selective internal radiation therapy for
intrahepatic cholangiocarcinoma: Data from clinical trials.
Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544. PubMedAbstract available
Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine
monophosphate production and extracellular signal-regulated kinases 1 and 2
phosphorylation in polycystin-2-defective cholangiocytes.
Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484. PubMed
JEONG H, Yoo C Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive
extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535. PubMed
HU YF, Gu HF, Jin YW, Li FY, et al Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in
node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532. PubMed
June 2023
SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al Predictors of 6-year event-free survival in alagille syndrome patients treated
with maralixibat, an ileal bile acid transporter inhibitor.
Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502. PubMedAbstract available
EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis
before and after liver transplantation: Are there other challenges?
Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503. PubMed
May 2023
NEJAK-BOWEN K, Monga SP Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495. PubMedAbstract available
Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and
metastasis in intrahepatic cholangiocarcinoma.
Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040. PubMed
SHU L, Li X, Liu Z, Li K, et al Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and
progression by targeting HPGD and increasing PGE2 generation.
Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437. PubMedAbstract available
JEONG H, Kim KP, Jeong JH, Hwang DW, et al Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive
extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Hepatology. 2023;77:1540-1549. PubMedAbstract available
FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al Reply: Living donor liver transplantation for people with PSC.
Hepatology. 2023;77:E97-E98. PubMed
April 2023
MACKOWIAK B, Gao B Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416. PubMed
RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial
repair in biliary atresia.
Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418. PubMedAbstract available
DANIEL N, Genua F, Jenab M, Mayen AL, et al The role of the gut microbiome in the development of hepatobiliary cancers.
Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406. PubMedAbstract available
HARTL L, Reiberger T, Trauner M Reply: progressive cholestasis and associated sclerosing cholangitis are
complications of COVID-19 in patients with chronic liver disease.
Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399. PubMed
UMAR S, Nadeem A, Nadeem M Letter to the editor: progressive cholestasis and associated sclerosing
cholangitis are complications of COVID-19 in patients with chronic liver disease.
Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398. PubMed
HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al Seladelpar efficacy and safety at 3 months in patients with primary biliary
cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395. PubMedAbstract available
YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally
advanced/metastatic biliary tract cancers.
Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365. PubMedAbstract available
CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ
activity and shows translational relevance to humans.
Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376. PubMedAbstract available
SINGH SP, Mondia N Letter to the Editor: Much more needed in natural history of Alagille syndrome.
Hepatology. 2023;77:E78. PubMed
January 2023
CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in
cholangiocarcinoma.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206. PubMedAbstract available
HEINEMANN M, Adam R, Karam V, Schramm C, et al Letter to the Editor: Living donor liver transplantation for people with PSC.
Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208. PubMed